PURPOSE OF REVIEW: Transfer of human regulatory T cells (Tregs) has become an attractive therapeutic alternative to improve the long-term outcome in transplantation and thus reduce the side-effects of conventional immunosuppressive drugs. Here, we summarize the recent findings on human Treg subsets, their phenotype and in-vivo function. RECENT FINDINGS: In the last 2 years, it has become apparent that several Treg subsets exist that specifically regulate Th1-driven, Th2-driven, or Th17-driven immune responses; these subsets are very unstable and rapidly change their phenotype, for example, there is loss of Foxp3 expression upon extensive ex-vivo expansion and only the administration of rapamycin has been shown to be able to interfere reproducibly. New humanized mouse models incorporating human solid-organ grafts have been developed, which have been used to test the human Treg in-vivo function, and the first human Treg-cell products have been tested for safety and efficacy in stem cell transplantation. SUMMARY: With the recent findings, we have gained a better understanding of Treg heterogeneity, plasticity and function. Using the outcomes of clinical trials in stem cell transplantation, we have learned that adoptive therapy of Tregs is well tolerated and we are now awaiting the first result in solid-organ transplantation from the 'ONE Study'.
PURPOSE OF REVIEW: Transfer of human regulatory T cells (Tregs) has become an attractive therapeutic alternative to improve the long-term outcome in transplantation and thus reduce the side-effects of conventional immunosuppressive drugs. Here, we summarize the recent findings on human Treg subsets, their phenotype and in-vivo function. RECENT FINDINGS: In the last 2 years, it has become apparent that several Treg subsets exist that specifically regulate Th1-driven, Th2-driven, or Th17-driven immune responses; these subsets are very unstable and rapidly change their phenotype, for example, there is loss of Foxp3 expression upon extensive ex-vivo expansion and only the administration of rapamycin has been shown to be able to interfere reproducibly. New humanized mouse models incorporating human solid-organ grafts have been developed, which have been used to test the human Treg in-vivo function, and the first human Treg-cell products have been tested for safety and efficacy in stem cell transplantation. SUMMARY: With the recent findings, we have gained a better understanding of Treg heterogeneity, plasticity and function. Using the outcomes of clinical trials in stem cell transplantation, we have learned that adoptive therapy of Tregs is well tolerated and we are now awaiting the first result in solid-organ transplantation from the 'ONE Study'.
Authors: Christian Morath; Anita Schmitt; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist Journal: Langenbecks Arch Surg Date: 2015-06-17 Impact factor: 3.445
Authors: D Berglund; M Karlsson; A-R Biglarnia; T Lorant; G Tufveson; O Korsgren; B Carlsson Journal: Clin Exp Immunol Date: 2013-08 Impact factor: 4.330
Authors: Joshua Weiner; Raimon Duran-Struuck; Jonah Zitsman; Leo Buhler; Hugo Sondermeijer; Alicia N McMurchy; Megan K Levings; Megan Sykes; Adam Griesemer Journal: Transplant Direct Date: 2015-02-01
Authors: Joost F Swart; Eveline M Delemarre; Femke van Wijk; Jaap-Jan Boelens; Jürgen Kuball; Jacob M van Laar; Nico M Wulffraat Journal: Nat Rev Rheumatol Date: 2017-02-23 Impact factor: 20.543
Authors: Sebastián A Riquelme; Leandro J Carreño; Janyra A Espinoza; Juan Pablo Mackern-Oberti; Manuel M Alvarez-Lobos; Claudia A Riedel; Susan M Bueno; Alexis M Kalergis Journal: Immunology Date: 2016-04-01 Impact factor: 7.397
Authors: Birgit Sawitzki; Claudio Brunstein; Christian Meisel; Julia Schumann; Katrin Vogt; Christine Appelt; Julie M Curtsinger; Michael R Verneris; Jeffrey S Miller; John E Wagner; Bruce R Blazar Journal: Biol Blood Marrow Transplant Date: 2013-11-01 Impact factor: 5.742